Extended Data Table 1.

Summary of protocol phases/versions and amendments submitted to FDA and oversight committees

B-VEC has been administered to nine (9) patients, in twelve (12)^a siloed participant treatment applications. Patients (IDs: Pts 1-12)^a enrolled separately onto one of 4 versions of the Phase 1 and 2 protocol. A summary of the protocols and patients enrolled are presented below. ^aThree patients were enrolled into both Phase 2a and Phase 2b. These patients’ Phase 2b wounds were treatment-naïve except for a chronic (5 year) dorsal foot wound on Pt 3. A wash-out period of 3 months passed between treatments in Phase 2a and 2b. Patients were enrolled in Phase 2a as Pts 3, 5, and 6 and in Phase 2b as Pts 11, 8, and 7, respectively. Pts # refer to patient identification numbers 1-12, nine total patients enrolled, three enrolled in both 2a and 2b with unique identification number. ^bProtocol versions represent intended design which was amended in consultation and with approval from oversight committees and regulatory authorities; protocol amendments correspond to Phases (1, 2a, 2b, 2c). *v3.2 clarified the long-term follow-up. B-VEC, beremagene geperpavec; Pt, Patient.